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Background Patients with repaired tetralogy Fallot often develop severe pulmonary regurgitation (PR) and need surgical or
catheter valve replacement/implantation. Early valve failure is not expected and thrombosis of a biological valve in
a mid-term period after surgery on pulmonary position is rare.
...................................................................................................................................................................................................
Case summary We report a 33-year-old female patient, who presented with heart failure, 18 months after surgical implantation of
a biological valve on pulmonary position for severe PR, after previous complete repair. The patient was on anti-
coagulant therapy with novel oral anticoagulants (NOACs) for paroxysmal atrial fibrillation. After revealing a big
pulmonary valve (PV) thrombus as a cause of severe valve stenosis and right heart failure, patient was re-operated
without complication. After surgery a long-term warfarin therapy was introduced. The patient had an uneventful
9-month follow-up.
...................................................................................................................................................................................................
Discussion Thrombotic events after rivaroxaban therapy are rare in non-valvular disease and there is paucity of data for
NOAC therapy related to valve thrombosis. In our case, severe heart failure 1 year and a half after PV replace-
ment, in a patient taking anticoagulant therapy, was unexpected. The diagnosis of valve thrombosis was revealed by
echocardiography, and confirmed by computed tomography. We did not find any sign of thrombophilia, or any
mechanical reason for valve thrombosis.
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Learning points
• Pulmonary valve (PV) prosthesis failure, in patients after tetralogy of Fallot (TOF) repair and later PV replacement in majority of cases is
the result of degeneration, rather than thrombosis.
• Thrombosis of a tissue PV is rare in absence of thrombophilia, especially in patients treated with anticoagulant therapy.
• Heart failure in early to mid-term period after PV replacement can be a result of tissue valve thrombosis.
• Therapy with novel oral anticoagulant rivaroxaban, might not prevent valve thrombosis.
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Introduction
Pulmonary regurgitation (PR) is common after tetralogy of Fallot
(TOF) surgical repair. It is increasingly recognized that right-sided
valve disease is not a benign lesion and that it has a significant and an
independent impact on morbidity and mortality.1 Surgical procedure
often involves pulmonary valvulotomy, a transannular patch, or inci-
sion in the right ventricular (RV) infundibulum, which can all contrib-
ute to long-term PR.2 Despite being well tolerated for a long time,
there is evidence that PR leads to progressive RV dilatation and ec-
centric hypertrophy. With time, it can be conducive to RV dysfunc-
tion, exercise intolerance, ventricular arrhythmias, and, rarely, a
sudden cardiac death.3 Dilatation and failure of the RV can be pre-
vented by valve replacement.4 Surgical bioprosthetic valves will even-
tually degenerate. In pulmonary position, this can be expected to
occur 5–10 years after implantation.5
Apart from valve degeneration, endocarditis can also be the cause
of pulmonary valve (PV) failure. Valve thrombosis is considered rare.6
Long-term anticoagulant therapy for tissue valves is not indicated.7
There is, however, a positive effect on biological valve thrombosis,
when there is a suspicion of it.8 There is so far no evidence of any
positive influence of novel oral anticoagulants (NOACs) on valvular
thrombus formation.
We present a case of surgical tissue PV obstruction caused by a big
thrombus in a patient on anticoagulation therapy with rivaroxaban.
Timeline
Case presentation
A 33-year-old female patient was admitted to our Clinic with severe
heart failure. She was referred for the first time 2 years earlier, as an
emergency, for atrial flutter, frequency 215/min. An immediate cardi-
oversion was performed, followed by electrophysiology and radiofre-
quency ablation and anticoagulant therapy with NOACs was
introduced for paroxysmal atrial fibrillation (AF).
The young woman is an adult congenital heart disease patient, after
surgical correction of TOF at the age of 4 years. She underwent ven-
tricular septal defect (VSD) closure, right ventricle outflow tract re-
section, and PV repair with a Dacron annular patch. She has regularly
been followed by an adult cardiologist without expertise in congenital
heart disease.
At her first presentation in our hospital, echocardiographic
(ECHO) examination revealed a dilated RV with already reduced sys-
tolic function and volume overload, dilated tricuspid annulus, and
intermediate tricuspid regurgitation, with no evidence of residual
VSD, obstruction of PV and pulmonary hypertension. A significant PR
was observed, confirmed by cardiac magnetic resonance imaging,
with regurgitation fraction of 41% and diastolic volume of the RV of
233 mL (116 mL/m2), with RV ejection fraction of 48%.
A surgical procedure was proposed. Pulmonary valve prosthesis
implantation (SJM Biocor A 25 mm), tricuspid anuloplasty (Edwards
MC 3 Tricuspid Ring 34 mm) and patch reconstruction of pulmonary
artery (BioIntergral Surgical Patch) was successfully performed.
Clinical recovery was fast, and postoperative ECHO indicated good
function of biological prosthesis on PV position, and reduction of RV
volume.
One year and a half after the surgery, the clinical course was un-
eventful. The patient was treated by anticoagulation therapy with
warfarin 3 months after surgery, followed by rivaroxaban 20 mg daily,
for paroxysmal AF.
She arrived again 18 months later, with right heart failure, after a
month of progressive effort intolerance. The ECHO revealed
again the dilatation of RV, this time with signs of pressure overload,
and pulmonary pressure gradient of 110 mmHg (Figure 1).
Transoesophageal ECHO (TOE) established an organized thrombus
formation on the prosthesis, measuring 25  10 mm with an add-
itional floating formation of 8 5 mm and a residual valve ‘tunnel’ of
8 mm (Figure 2). The findings of electrocardiogram-triggered pul-
monary computed tomography (CT) angiography were similar
(Figure 3A and B). We did not found thrombophilia, or a mechanical
reason for valve thrombosis.
Reoperation was proposed and performed: excision of a throm-
bosed tissue valve and re-implantation of St. Jude Biocor valve A
25 mm, in pulmonary position. The patient made a good postopera-
tive recovery. A long-term anticoagulation therapy with warfarin was
induced. Postoperative ECHO showed reduction of RV volume and
an improvement in systolic function. The PV gradient was 25 mmHg.
The 9-month follow-up was uneventful.
Discussion
Pulmonary valve replacement after repair of TOF is recommended
before the occurrence of RV dysfunction, but the timing is still
.................................................................................................
Date Events
1989 Total repair of tetralogy of Fallot
6 April 2016 Emergency admittance for atrial flutter. Successful
ablation was performed. For paroxysmal atrial
fibrillation (AF), anticoagulation therapy with
rivaroxaban was started
30 May 2016 Pulmonary tissue valve implantation for severe re-
gurgitation with excellent postoperative recov-
ery. Warfarin therapy for 3 months followed by
rivaroxaban for AF
20 December
2017
Admitted to our department for severe heart fail-
ure (clinical deterioration 4 weeks before admis-
sion). Biological pulmonary valve (PV)
thrombosis was diagnosed, and fractionated hep-
arin was introduced
28 December
2017
Reoperation: replacement of a thrombosed tissue
valve. Uneventful postoperative course. Warfarin
for long-term therapy introduced (target INR
2.5–3)
9 October
2018
Clinically without events, on transthoracic echocar-
diogram normal PV function without thrombus
formation
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controversial. Cardiac magnetic resonance imaging has become
accepted as the gold standard for the assessment of RV remodelling.9
Despite RV diastolic volume was less than recommended for PV re-
placement, considering our patients RV volume overload, along with
rhythm disturbances, a decision for PV replacement was made.
The effects of PR on some electrocardiographic predictors of
arrhythmia, for example AF, are not clear. Restoration of PV
competence often leads to stabilization or reduction of QRS duration
with a corresponding decrease in arrhythmia.10 In our case, the atrial
flutter was the first presentation of hemodynamic deterioration, a
long time after TOF repair.
Data concerning the best tissue valve prosthesis for use in the pul-
monary position are scarce.11 Literature describes several factors
which influence the time of valve degeneration: the timing of surgery,
Figure 1 Continuous-wave Doppler tracing indicating severe pulmonary stenosis with maximum pressure gradient of 100 mmHg.
Figure 2 Transoesophageal echocardiogram showing thrombotic mass extending across prosthetic pulmonary valve into the pulmonary trunk
(arrows).
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the patient’s age, valve size, immunological factors, operative com-
plexity, and also postoperative valve gradients.12
Bio-prosthetic valve thrombosis is a rare event, which may occur
late after surgery.13 Patients with tissue heart valve prosthesis still
have a risk of developing valve thrombosis and arterial thrombo-
embolism. Antithrombotic therapy with warfarin in the early postop-
erative period is controversial, but still recommended.14 Our patient
was treated with warfarin for up to three months following surgery,
whereupon rivaroxaban was introduced, for long-term thrombo-
embolic protection after paroxysmal AF.
In patients with AF, rivaroxaban was not inferior to warfarin for
the prevention of stroke or systemic embolism.15 Although there is
no evidence of NOAC activity in thrombotic events in valve disease,
presence of any valvular disease did not influence the comparison of
dabigatran with warfarin, and no difference in events was found.16
A fixed-dose regimen of rivaroxaban alone showed no inferiority to
standard therapy for the initial and long-term treatment of pulmonary
embolism and had a potentially improved risk benefit profile. Novel
oral anticoagulants appear to be safe and effective in adult patients
with congenital heart disease.17 There are no published data about in-
fluence of rivaroxaban or other NOACs on thrombotic events
related to surgical tissue valves.
Echocardiographic plays an important role to the diagnosis of bio-
logical valve thrombosis and CT may be of added value.18 In our pa-
tient, PV thrombosis was first revealed by TOE, and then confirmed
by CT.
Bioprosthetic valves are generally considered to carry a low risk of
thrombosis and only few reports exist of the valve thrombosis.
Majority data refer to left heart mechanical valves thrombosis.19 For
the management, thrombolytic therapy has been suggested as an al-
ternative to surgery. It is associated with lower mortality rate but car-
ries the risk of embolism, bleeding, and re-thrombosis. The optimal
treatment of biological valve thrombosis is still a matter of debate.
Anticoagulation and operative intervention are the mainstay of treat-
ment. A response to anticoagulation therapy is usually observed
4–12 weeks after initiation.13 In our case, repeated surgery was per-
formed, expecting complete haemodynamic success in a patient with
high functional class, big thrombus burden, severe valve obstruction
and low surgical risk.20
Supplementary material
Supplementary material is available at European Heart Journal - Case
Reports online.
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